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Perspective 
Behçet’s  disease  as  a  systemic  vasculitis  is  mainly 
characterized  by  recurrent  of  remission  and  the 
exacerbation  of  oral,  genital  ulcers,  and  uveitis. 
Inflammatory  symptoms  may  manifest  as 
mucocutaneous  lesions,  arthritis,  venous  thrombosis, 
arterial aneurysms, intestinal ulcers, pulmonary lesions 
and central nervous system lesions.
1 
Behçet’s disease has been reported worldwide, but has 
a  peculiar  geographic  distribution  with  highest 
prevalence in countries along the ancient silk route.
2  
Etiology  and  exact  mechanisms  of  pathogenesis 
remains  unidentified  but  a  boosted  and  dysregulated 
immune  response  has  been  proposed  as  the  principal 
pathology. Microorganisms (viral and bacterial agent) 
may play a role as a trigger in genetically susceptible 
subjects.
3  
The genetic defects commonly result in a constant low-
grade  inflammatory  activity;  though  intermittent 
inflammatory  attacks  at  involved  positions  determine 
the  clinical  picture.  Enhanced  inflammatory  response 
like increased neutrophil functions such as chemotaxis, 
phagocytosis,  and  excessive  production  of  reactive 
oxygen  species  (ROS)  and  over-expression  of 
proinflammatory cytokines such as IL-8, IL-17, IFN-γ, 
and TNF-α are the prominent features responsible for 
damage in Behçet’s disease.
4,5 
Traditionally,  BD  is  regarded  as  a  Th1-mediated 
inflammatory  disease  but  prospective  observational 
studies  recommend  that  Th17  (a  novel  subset  of  T 
cells),  plays  a  fundamental  role  in  pathogenesis  of 
Behçet's  disease,  and  genome-wide  association 
researches  confirmed  it.
6  Furthermore,  an  increase  of 
IL-17  production  has  been  detected  in  rheumatoid 
arthritis,  inflammatory  bowel  disease,  and  multiple 
sclerosis. These results recommend that dysregulation 
of Th17 cells may be involved in the pathogenesis of 
Behçet's diseases.
7 
Th17  cells  predominantly  produce  IL-17A-F,  IL-21, 
IL-22 and TNF-alpha. IL-6 and TGF-beta induce the 
differentiation of Th17 cells from naive T cells. IL-17, 
which  is  the  secreted  from  of  Th17,  activate 
neutrophils.  Hence,  IL-17  might  cause  the  symptoms 
resembling  autoinflammatory  diseases.  Activated 
neutrophils  secrete  some  cytokines  which  stimulate 
Th17 cytokines like IL-21 and IL 17-A. The increased 
production of IL-17 and IL-21 has been demonstrated 
in  Behçet’s  disease.
8  Chi  et  al.  stated  that  the 
production  of  IL-23  and  IL-17  by  PBMCs  was 
upregulated in patients  with BD.
9 On  the other  hand, 
the presence of the IL-21 and IL17-A producing T cells 
was  demonstrated  in  the  cerebrospinal  fluid,  brain 
parenchyma inflammatory infiltrates, and intracerebral 
blood  vessels  of  patients  with  active  BD  and  central 
nervous  system  involvement.
  IL-17A  and  IL-21 
represents a promising target for novel therapy in BD.
7 
Neutrophils play an essential role in innate immunity. 
They  are  the  most  dominant  leucocytes  and  respond 
rapidly to chemotactic stimuli, phagocyte and destroy 
foreign  particles  using  their  oxidative  and  non-
oxidative  destroying  mechanisms  for  pathogen 
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Behçet Disease (BD) is an autoimmune disorder with recurrent ocular, vascular, central 
nervous  system,  articular,  mucocutaneous,  and  gastrointestinal  manifestations  with 
unclear  etiology  and  pathogenesis.  The  further  characterization  of  inflammatory 
features of Behçet’s disease may eventually lead to development of better treatment 
options. Clinical and laboratory observations suggested an important role of IL-17, IL-
21  and  neutrophil-mediated  process  in  the  pathogenesis  of  BD.  New  therapeutic 
modalities  target  specific  and  nonspecific  suppression  of  the  immune  system.    The 
various non-specific immunosuppressive drugs, used either alone or in combinations, 
frequently  fail  to  control  inflammation  or  maintain  remissions.  Due  to  encouraging 
clinical results (i.e. Antigenic specification, prolonged survival with acceptable levels 
of toxicity); antibody-based drugs could be effective for the clinical management of 
Behçet’s disease.  
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elimination.  Functional  abnormalities  in  any  steps  of 
these  may  cause  following  defective  response  in 
immune system.
10 Hyperactivity of the neutrophils is an 
important aspect of the immunological abnormalities in 
BD.
 
Before going directly to neutrophils function in lesions 
of BD, proof of concept studies relevant if perspectives 
are  needed.  Biopsy  specimens  from  active  lesions  of 
BD display large amounts of neutrophils in the absence 
of  infection,  and  neutrophils  from  patients  with  BD 
show increased superoxide anion production, enhanced 
chemotaxis, and excessive release of granular enzymes, 
which indicate neutrophil hyperactivity in BD.
11  
Several proinflammatory cytokines, such as interleukin 
17 and 21 are proposed to be accounted for the priming 
of  neutrophil  activation  and  the  enhanced  cellular 
interactions between neutrophils and endothelial cells. 
Moreover,  IL-17  involved  in  the  recruitment  of 
neutrophils to the site of inflammation.
12,13 Neutrophil 
hyperactivity  and  elevated  inflammatory  cytokine 
levels  are  hallmarks  of  BD.  Neutrophils  produce 
inflammatory  cytokines,  which  promote  neutrophil 
activity.  This  makes  a  cycle  in  which  elevated  and 
activated neutrophils produce more cytokines and the 
latter enhance neutrophil activity.
14 
The  primary  goals  of  BD  management  are  symptom 
control, soothing the inflammation and suppression of 
the  immune  system  and  prevention  of  end-organ 
damage.  The  treatment  options  must  be  anti-
inflammatory  agents  and  immunosuppressant  but  in 
severe  stages,  may  be  resistant  to  all  forms  of 
immunosuppression.  Conventional  therapeutic 
approaches suppress the activity of the leucocytes and 
lymphocytes.
15  Drugs  are  frequently  used  in 
combination  to  maximize  efficacy  while  minimizing 
side effects.  
Conventional  therapeutic  approaches  suppress  the 
activity  of  the  leucocytes  (anti-inflammatory)  and 
lymphocytes  (immunosuppressive)  in  T-cell-mediated 
diseases.  Now  colchicine  has  been  widely  used  as  a 
basic drug for treatment of Behçet’s disease and applies 
beneficial  effects  through  inhibition  of  neutrophil 
functions as well as neutrophils chemotaxis.
16  
In  this  era,  by  the  advent  of  Monoclonal  antibodies 
(mAb)  directed  against  any  antigens  of  interest, 
Immunodrugs  (drug  immunoconjugates), 
Immunocytokines  (Recombinant  mAb-cytokine  fusion 
proteins),  immunotherapy  based  on  mAb-therapy  of 
human  autoimmune  disease  have  been  introduced.
17 
During  the  last  ten-year  period,  Infliximab  (chimeric 
anti-TNF-αmonoclonal  antibody),  Adalimumab 
(humanized  anti-TNF-αmonoclonal  antibody)  and 
Etanercept (fusion protein human p75 TNF-α receptor 
IgG1)  are  increasingly  used  for  patients  with  BD. 
Because clinical and laboratory observations suggested 
that  TNF-mediated  process  in  the  pathogenesis  of 
BD.
18  
The  further  characterization  of  inflammatory  features 
of  Behçet’s  disease  may  eventually  lead  to 
development  of  better  treatment  modalities.  Clinical 
and laboratory observations proposed a central role of 
IL-17 and IL-21 and neutrophil-mediated process in the 
pathogenesis  of  BD.  This  result  indicates  correlation 
between  neutrophil  biology,  IL-17  and,  IL-21  with 
Behçet’s  disease.  Considering  the  fact  that  if  in  new 
studies,  researcher  focuses  in  these  perspectives,  it 
could be possible find better aspect in Behçet’s disease 
therapy  based  on  its  immunophatogenesis.  Due  to 
encouraging  clinical  results  (i.e.  Antigenic 
specification, prolonged survival with acceptable levels 
of  toxicity);  antibody-based  drugs  could  be  effective 
for the clinical management of Behçet’s disease. 
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